Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Mikus

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
Der Internist|February 4, 2010
[Drug interactions]V Hafner, B Grün, C Markert, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1994
Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphismG Mikus, F Bochner, M Eichelbaum, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1990
Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug actionG Mikus, M Eichelbaum, C Fischer, et al.
Pharmacogenetics|January 14, 2000
Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African populationE U Griese, S Asante-Poku, D Ofori-Adjei, et al.
Clinical Pharmacology and Therapeutics|March 21, 2013
A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactionsB Halama, N Hohmann, J Burhenne, et al.
European Journal of Clinical Pharmacology|January 1, 1986
Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteineG Mikus, H R Ha, S Vozeh, et al.
Clinical Pharmacology and Therapeutics|April 1, 1997
Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotypeG Mikus, B Trausch, C Rodewald, et al.
Clinical Pharmacology and Therapeutics|September 23, 2011
Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategyS Katzenmaier, C Markert, K-D Riedel, et al.
Klinische Wochenschrift|December 2, 1985
Pharmacokinetics of oral and intravenous rifampicin during chronic administrationU Loos, E Musch, J C Jensen, et al.
Clinical Pharmacology and Therapeutics|September 1, 1996
The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humansD A Capon, F Bochner, N Kerry, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
Der Internist|February 4, 2010
[Drug interactions]V Hafner, B Grün, C Markert, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1994
Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphismG Mikus, F Bochner, M Eichelbaum, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1990
Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug actionG Mikus, M Eichelbaum, C Fischer, et al.
Pharmacogenetics|January 14, 2000
Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African populationE U Griese, S Asante-Poku, D Ofori-Adjei, et al.
Clinical Pharmacology and Therapeutics|March 21, 2013
A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactionsB Halama, N Hohmann, J Burhenne, et al.
European Journal of Clinical Pharmacology|January 1, 1986
Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteineG Mikus, H R Ha, S Vozeh, et al.
Clinical Pharmacology and Therapeutics|April 1, 1997
Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotypeG Mikus, B Trausch, C Rodewald, et al.
Clinical Pharmacology and Therapeutics|September 23, 2011
Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategyS Katzenmaier, C Markert, K-D Riedel, et al.
Klinische Wochenschrift|December 2, 1985
Pharmacokinetics of oral and intravenous rifampicin during chronic administrationU Loos, E Musch, J C Jensen, et al.
Clinical Pharmacology and Therapeutics|September 1, 1996
The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humansD A Capon, F Bochner, N Kerry, et al.
Pageof 9